Searched for
LAURUS LABS UNDERPERFORM
Nifty stuck in a range but small and midcaps are where real money is being made: Ashish ChaturmohtaIndian stock markets may appear stagnant, but opportunities exist in small and midcap stocks. JM Financial's Ashish Chaturmohta highlights ...- Rising bond yields, oil prices keeping markets on edge; selective bets still emerging: Pankaj PandeyGlobal markets are under pressure due to rising bond yields and geopolitical tensions. Higher crude oil prices are a key concern, potential...
- Jefferies' pharma bets are Divi's Laboratories and 3 smallcaps, with up to 30% upside. Here's whyJefferies expects India’s CRDMO sector to see strong growth over 3–5 years, recommending Divi’s Labs, Cohance Lifesciences, Sai Life Scienc...
- Bharti Airtel outperforms; Vodafone Idea remains a value trap: Hemang JaniMarket expert Hemang Jani suggests Laurus Labs' earnings may improve with new launches. API business is also showing promise. He prefers La...
- Short covering anticipated next week; bullish on 4 pharma & defence stocks: CA Rudramurthy BVCA Rudramurthy BV sees a buying opportunity in Nifty and Bank Nifty. Nifty is expected to find strong support at 25,000. Bank Nifty has bro...
- Balance between large and small-caps, investment in cos with single-focus—should Sundaram Mid-cap fund make it to your portfolio?We examine the key fundamentals of the Sundaram Mid-cap fund, its portfolio, and performance to help you make an informed investment decisi...
- Hot stocks: Brokerage view on Ramco Cements, Tech Mahindra, Laurus Labs, Syngene and CyientCiti has maintained a sell call on Ramco Cements, raising the target price to Rs 750 from Rs 735. Despite stable EBITDA per ton, Ramco has ...
- Foram Chheda on Nifty's volatility and key stock picks“Since August, Laurus Labs stock price has been underperforming and it actually went from the levels of 400 odd to nearly 350. But 350 turn...
- Nifty, Bank Nifty can drift lower; 2 top stock picks now: CA RudramurthyCA Rudramurthy BV, Vachana Investments, recommends buying ICICI Bank with a target of Rs 1,000 and Escorts with targets of 3,300 and 3,500....
- Hot Stocks: Brokerages on Shriram Finance, ACC, Nestle India, and Laurus LabsHSBC maintained a buy rating on Shriram Finance with a target price of Rs 228. A 4% profit beat was led by lower provisions despite higher-...
- Biceps missing in bull market? Every third Nifty500 stock at least 20% away from peakDespite Sensex and Nifty reaching record highs in the last 3 months, a study of Nifty 500 stocks reveals that 185 stocks are at least 20% a...
- Franklin India Equity Advantage mutual fund review: Weak long-term return profile; should you stay invested?We examine the key fundamentals of the fund, its portfolio and performance to help you make an informed investment decision.
- Pharma stocks continue to underperform in 2023. Should investors take the bitter pill?The Nifty Pharma Index fell about 6% so far this year on a year-to-date basis. The price pressure in US generic market is seen as a key dra...
- How the richie rich made money in a lacklustre marketSaurabh Mukherjea’s Little Champs outpaced its benchmark to deliver nearly 3 per cent. Sunil Singhania’s Emerging Opportunities Fund and Bh...
- Midcap pharma regains its vigour on Dalal StreetSo far this week, Nectar Life has gained 36 per cent, Morepen has risen 30 per cent, Panacea has moved up 28 per cent Suven Life has advanc...
- Out of 10 biggest small investor bets, only one shone in 2020; 9 eroded wealthAll stocks but Laurus Labs delivered poor returns: seven of them ended up eroding up to 77 per cent of investor wealth; two delivered a tep...
- 4 pharma stocks Hemang Jani is betting onDivi’s Lab could be one stock which can do exceptionally well despite the kind of run up that we have seen in the last let us say six month...
- Ashok Leyland may prove to be the dark horse in auto space: Abhimanyu SofatConsidering the stock is quite diversified, from commercial vehicles to defence, you could see a lot of traction coming over next two-three...
- FPIs, MFs both turn gung-ho on these 12 stocks; they’re worth a lookDomestic mutual funds and foreign portfolio investors (FPIs) both turned bullish on at least a dozen common stocks in June quarter.
- Market movers: Aurobindo shines, but many pharma stocks overbought; 280 stocks hit upper circuitsA fast rising tally of Covid cases did not help investor sentiment.
Load More
